{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05737615",
            "orgStudyIdInfo": {
                "id": "20-409"
            },
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9",
            "officialTitle": "A Phase I Study of Pretargeted PET Imaging Using 64Cu-Tz-SarAr and a Trans-Cyclooctene-Modified Humanized 5B1 Immunoconjugate (hu5B1-TCO) in Patients With Pancreatic, Bladder Cancer, Gastrointestinal Malignancies or Solid Tumors With Elevated CA19-9",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "pet-imaging-using-tz-sarar-and-tco-in-people-with-pancreatic-colorectal-bladder-cancer-or-cancers-with-elevated"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2023-02-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-10",
            "studyFirstSubmitQcDate": "2023-02-10",
            "studyFirstPostDateStruct": {
                "date": "2023-02-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to find the highest safe dose of hu5B1-TCO and the best dosing schedule of hu5B1-TCO and 64Cu-Tz-SarAr for finding cancer cells that are CA19-9 positive. This study will also help to find out how much radiation the body is exposed to when 64Cu-Tz-SarAr is used, and provide information on the way the body absorbs, distributes, and gets rid of 64Cu-Tz-SarAr."
        },
        "conditionsModule": {
            "conditions": [
                "Pancreatic Cancer",
                "Pancreatic Ductal Adenocarcinoma",
                "Metastatic Pancreatic Ductal Adenocarcinoma",
                "Primary Pancreatic Ductal Adenocarcinoma",
                "Metastatic Pancreatic Cancer"
            ],
            "keywords": [
                "Pancreatic Cancer",
                "Pancreatic Ductal Adenocarcinoma",
                "Metastatic Pancreatic Ductal Adenocarcinoma",
                "Primary Pancreatic Ductal Adenocarcinoma",
                "Metastatic Pancreatic Cancer",
                "hu5B1-TCO",
                "64Cu-Tz-SarAr",
                "20-409",
                "Memorial Sloan Kettering Cancer Center"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 22,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Participants with Pancreatic Cancer",
                    "type": "EXPERIMENTAL",
                    "description": "Participants have histologically confirmed primary or metastatic pancreatic ductal adenocarcinoma",
                    "interventionNames": [
                        "Diagnostic Test: PET Scan",
                        "Drug: hu5B1-TCO",
                        "Drug: 64Cu-Tz-SarAr",
                        "Diagnostic Test: Pharmacokinetics"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "PET Scan",
                    "description": "Participants will be imaged up to 4 time points post-injection to allow for biodistribution and dosimetry determination",
                    "armGroupLabels": [
                        "Participants with Pancreatic Cancer"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "hu5B1-TCO",
                    "description": "On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.",
                    "armGroupLabels": [
                        "Participants with Pancreatic Cancer"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "64Cu-Tz-SarAr",
                    "description": "On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.",
                    "armGroupLabels": [
                        "Participants with Pancreatic Cancer"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Pharmacokinetics",
                    "description": "All participants receiving 64Cu-Tz-SarAr will have serial blood samples drawn.",
                    "armGroupLabels": [
                        "Participants with Pancreatic Cancer"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "SUV mean measurement",
                    "description": "The serial quantitative data obtained over the various organs of interest (heart, liver, spleen, kidney, lung and any other organ that exhibits uptake) will be collected",
                    "timeFrame": "28 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nPatients will be eligible for enrollment if they fulfill the following criteria:\n\n1. Signed informed consent\n2. 18 years of age or older\n3. Histologically confirmed primary or metastatic pancreatic ductal adenocarcinoma/bladder carcinoma / gastrointestinal tumor reviewed at MSK - includes patients with biopsy-proven or high suspicion on imaging for pancreatic ductal adenocarcinoma (PDAC) or histologically confirmed, locally-advanced, or metastatic pancreatic ductal adenocarcinoma (PDAC) of\n\nPatient with solid tumors increased serum CA19-9 serum level greater than ULN or CA19-9 positive biopsy\n\n4. At least one lesion by CT or MRI \u2265 2 cm unless determined otherwise for presurgery subjects 5. ECOG performance status of 0 to 2 6. Adequate laboratory parameters including: i. Absolute neutrophil count (ANC) \u22651.5 x 109/L ii. Hemoglobin \u2265 9.0 g/dL iii. Platelet count \\>75,000/ mm3 iv. AST/SGOT, ALT/SGPT \u22642.5 x ULN, unless liver metastases are clearly present, then \u22645.0 x ULN v. Total bilirubin \u2264 1.5x the upper limit of normal unless considered due to Gilbert's syndrome in which case, \u22643x the upper limit of normal vi. Creatinine clearance (CLcr) (\\> 60 mL/min) estimated by the Cockcroft-Gault (C-G) equation or estimated glomerular filtration rate (eGFR) 10. Willingness to participate in collection of pharmacokinetic samples\n\nExclusion Criteria:\n\nPatients will be excluded from the study if they fulfill any of the following criteria:\n\n1. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy\n2. Major surgery other than diagnostic surgery within 4 weeks of Study Day 1\n3. History of anaphylactic reaction to human, or humanized, antibody\n4. Other on-going cancer therapy with investigational agents\n5. Known history of HIV\n6. Pregnant or currently breast-feeding\n\n   a. Subjects and their partners with reproductive potential must agree to use an effective form of contraception during the study and for 1 week following the study treatment.\n7. Psychiatric illness/social situations that would interfere with compliance with study requirements.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Neeta Pandit-Taskar, MD",
                    "role": "CONTACT",
                    "phone": "2126393046",
                    "email": "pandit-n@MSKCC.ORG"
                },
                {
                    "name": "Eileen O'Reilly, MD",
                    "role": "CONTACT",
                    "phone": "6468884182",
                    "email": "oreillye@MSKCC.ORG"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Neeta Pandit-Taskar, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Neeta Pandit-Taskar, MD",
                            "role": "CONTACT",
                            "phone": "212-639-3046"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "http://www.mskcc.org"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000010190",
                    "term": "Pancreatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000010182",
                    "term": "Pancreatic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13102",
                    "name": "Pancreatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M20855",
                    "name": "Immunoconjugates",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}